Jagsonpal Pharmaceuticals Limited announced its unaudited financial results for the quarter and nine months ended December 31, 2025. The company reported a Profit After Tax (PAT) of ₹125 million for Q3 FY26, marking a 10% increase year-on-year. For the nine-month period ended December 31, 2025 (9MFY26), PAT grew by 12.5% to ₹359 million. Revenue for Q3 FY26 stood at ₹729 million, a slight decrease of 1% year-on-year, while the 9MFY26 revenue increased by 6% to ₹2,230 million. Operating EBITDA for Q3 FY26 was ₹166 million, with an EBITDA margin of 22.7%. For the nine-month period, Operating EBITDA grew 5% year-on-year to ₹503 million. The company highlighted a robust free cash generation, with cash balances at ₹1,757 million as of December 31, 2025, an increase of ₹152 million during the quarter. Manish Gupta, Managing Director and CEO, expressed confidence in stronger growth going forward, starting from Q4 of the current fiscal, supported by focused initiatives and a strong balance sheet. The company's strategic focus includes new product launches, sales force empowerment, price increases for non-NLEM products, and inorganic growth through brand and business acquisitions. Jagsonpal Pharmaceuticals has a strong portfolio focusing on Gynaecology, Orthopaedics, Dermatology, and Child-care segments.
